What the successful SpaceX launch means for Tesla

Slack, Zoom, And The "Stay At Home" Economy—Q1 Earnings Preview

You've probably heard the saying that in every crisis lies a great opportunity. For Zoom Video Communications (NASDAQ: ZM), and Slack Technologies (NYSE: WORK), opportunity seems to have come this year in the unlikely form of a global pandemic. This week, both report earnings. The "Great Lockdown" may have decimated employment across most of the working world, but it also accelerated the groundwork for a new type of economic reality: Let's call it the "stay-at-home" economy. This new economy is all about virtualization--people working from home, educational institutions offering classes online, and fitness classes going online. And companies like ZM and WORK are arguably in a position to help power up the new virtual world and find themselves in the spotlight. ZM is a video conferencing platform designed for large meetings; up to 100 people can gather on the same screen. WORK is a channel-based instant messaging platform that allows communications...

Pfizer Analyst Takes Stock Of Negative Breast Cancer Data, Pharma Giant's 2025 Goals

Pfizer Inc. (NYSE: PFE) shares were declining steeply Monday after the company said a Phase 3 study dubbed PALLAS that evaluated its Ibrance with standard adjuvant endocrine therapy in HR+, HER-, early stage breast cancer study is unlikely to hit the primary goal, citing efficacy and futility analysis done by an Independent Data Monitoring Committee.The Pfizer Analyst Cantor Fitzgerald analyst Louise Chen maintained an Overweight rating on Pfizer shares with a $53 price target. The Pfizer Thesis The adjuvant opportunity for the breast cancer drug Ibrance is being viewed by investors as a key growth driver for Pfizer, Chen said in a Friday note. (See her track record here.)The analyst said she expects the consensus sales estimate for Ibrance to come down to reflect a lower opportunity.Pfizer had earlier said the adjuvant opportunity could double the eligible patient population for Ibrance, she said.Ibrance is already approved in the U.S. for treating...

JPMorgan’s Math Shows Why U.S. Stocks Can Keep Rallying

(Bloomberg) -- Think the sizzling U.S. stock rally is excessive in an economy frozen by shutdowns? From one perspective, it’s just getting started.Giant piles of cash sloshing around the financial system means there’s substantial ammunition yet to push risk assets higher. JPMorgan Chase & Co., meanwhile, sees potential for billions to flow into equities at the expense of bonds to rebalance portfolios. Money-market funds have lured $1.2 trillion this year, while fund managers with $591 billion overall are holding cash at levels rarely seen in history, according to Bank of America Corp.All that shows how much firepower investors have to support the market at a time when stock prices look unhinged from fundamentals like corporate profits, and trade frictions between China and the U.S. return to the forefront.“Investors are still underweight equities and signs of overextension are confined to momentum traders,” JPMorgan strategists led by Nikolaos Panigirtzoglou wrote in a note....